Translational Science and Therapeutics Division

Accelerating Clinical Advances in Cellular and Gene Therapies

The Translational Science and Therapeutics (TST) Division at Fred Hutchinson Cancer Center is composed primarily of laboratory-based research groups that work in areas related to hematopoiesis, immunology, hematopoietic cell transplantation, immunotherapy and gene therapy. The overall goal is to advance our understanding in these research areas and to develop next generation therapies for patients with hematologic malignancies and disorders, solid tumors and infectious diseases.

Dr. Geoff hill writes on a whiteboard

Advancing Research

Our faculty includes 51 researchers focused on developing treatment options, improving patient outcomes and identifying ways to prevent complications from treatments.

Dr. Stan Riddell looks through a microscoope

Developing Therapies

Our investigators are addressing less toxic techniques for eliminating diseased cancer cells and improving the chance of matching blood products for transplantation.

Latest TST News

All TST News
Conducting RNA reconnaissance Fred Hutch researchers invent a CRISPR screening method to understand RNA-binding proteins often mutated in cancer and other diseases August 5, 2025
‘Manufacturing scientist’ believes in the machinery that powers Fred Hutch’s cell therapies Dr. Folashade Otegbeye is the recipient of the Fleischauer Family Endowed Chair in Cell and Gene Therapy Translation July 30, 2025
A chair built together Collective fundraising effort honors Kyle Thomas Spane, fuels research in colon cancer prevention May 6, 2025
50 years of doing hard things Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure for blood diseases that changed medicine and became a world-class biomedical research and clinical care institution January 9, 2025